Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.
Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.
Examination the ability to early diagnose HCC by combining three biomarkers technology
 developed by WAKO, And their relevance to cirrhotic of patients with various backgrounds and
 the Israeli population.

 This blood test will serve as an additional diagnostic tool tools currently in use
 (Ultrasound and AFP levels) to cirrhotic patients with high risk to develop hepatocellular
 carcinoma.

 Another group that will be examined for all three biomarkers will be patients which already
 diagnosed with hepatocellular carcinoma, and have normal AFP level in order to examine the
 correlation between the presence of tumor, the number of them and the tumor size and the
 three biomarkers concentration in their blood
Inclusion Criteria:

 -  patients with chronic liver disease or cirrhotic or with diagnoses HCC with HCV, HBV,
 NAFLD, Alcohol background

 Exclusion Criteria:

 -  patients with chronic liver disease or cirrhotic or with diagnoses HCC with autoimmune
 background or other background than HCV, HBV, NAFLD and Alcohol.